$ 2.11
Key Takeaways
Risk factor
Very high price volatility
Profitability factor
Undervalued vs peers
About
Cassava Sciences, Inc., a clinical stage biotechnology company, develops drugs for neurodegenerative diseases. Its lead therapeutic product candidate is simufilam, a small molecule drug, which is completed Phase 2b clinical trial; and investigational diagnostic product candidate is SavaDx, a blood-based biomarker/diagnostic to detect Alzheimer's disease. The company was formerly known as Pain Therapeutics, Inc. and...
Company Valuation
Based on key historical and expected multiples, the stock is undervalued relative to its peers. In particular, the stock is 'cheap' on EV/EBITDA.
Target Price
The average target price of SAVA is 2.0 and suggests 5% downside potential. Usually, this means a SELL recommendation among investment firms, or a recommendation to decre
